Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cara Therapeutics
Biotech
Tvardi to go public via merger with cash-strapped Cara
Pruritus drug developer Cara kicked off the year halving its headcount and has now found a new home via a merger with fibrosis disease-focused Tvardi.
James Waldron
Dec 18, 2024 10:37am
Itch treater Cara cuts 50% of team to extend runway into 2026
Jan 22, 2024 9:44am
Mirati CMO, COO booted as request to FDA looms—Chutes & Ladders
Nov 5, 2021 9:30am
After securing first FDA nod in 17-year stint, Cara CEO departs
Nov 3, 2021 10:35am
Cara's stock tanks as atopic dermatitis phase 2 misses endpoint
Apr 30, 2021 8:25am
Cara posts positive phase 3 data, eyes 2020 filing for itch drug
Apr 21, 2020 7:00am
